Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

Summary Objective To investigate the pharmacokinetic profile of a prolonged release, aqueous Autogel® formulation of the somatostatin analogue lanreotide (Lan‐ATG). Design A phase II, randomized, double‐blind study, during which patients received 60, 90 or 120 mg Lan‐ATG for four fixed administrat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical endocrinology (Oxford) 2005-11, Vol.63 (5), p.514-519
Hauptverfasser:	Bronstein, M., Musolino, N., Jallad, R., Cendros, J. M., Ramis, J., Obach, R., Leselbaum, A., Catus, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acromegaly - drug therapy Acromegaly - metabolism Adult Analysis of Variance Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Biological and medical sciences Delayed-Action Preparations Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Endocrinopathies Female Fundamental and applied biological sciences. Psychology Gels Growth Hormone - blood Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Injections, Subcutaneous Insulin-Like Growth Factor I - analysis Linear Models Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Peptides, Cyclic - pharmacokinetics Peptides, Cyclic - therapeutic use Somatostatin - analogs & derivatives Somatostatin - pharmacokinetics Somatostatin - therapeutic use Vertebrates: endocrinology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!